deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT00822172

Evaluation of Cilostazol in Combination With L-Carnitine (ECLECTIC)

Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication

Sponsor: Colorado Prevention Center

Updated 8 times since 2017 Last updated: Nov 11, 2019 Started: Sep 30, 2008 Primary completion: Nov 30, 2010 Completion: Dec 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Intermittent Claudication and Peripheral Arterial Disease, this trial is completed. The trial is conducted by Colorado Prevention Center and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Dec 2019 · 18 months · monthly snapshotCompleted~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE4

Show 3 earlier versions
  1. Jun 2018 — Dec 2019 [monthly]

    Completed PHASE4

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Colorado Prevention Center
  • Otsuka Pharmaceutical Co., Ltd.
Data source: Colorado Prevention Center

For direct contact, visit the study record on ClinicalTrials.gov .